Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Tax Provisions: 2020-2025

Historic Tax Provisions for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to -$262,000.

  • Mirum Pharmaceuticals' Tax Provisions fell 175.50% to -$262,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $593,000, marking a year-over-year decrease of 67.61%. This contributed to the annual value of $1.0 million for FY2024, which is 3.94% up from last year.
  • Mirum Pharmaceuticals' Tax Provisions amounted to -$262,000 in Q3 2025, which was down 165.17% from $402,000 recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Tax Provisions ranged from a high of $1.0 million in Q1 2025 and a low of -$6.6 million during Q2 2022.
  • Moreover, its 3-year median value for Tax Provisions was $316,000 (2023), whereas its average is $290,000.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Tax Provisions crashed by 59,827.27% in 2022, and later surged by 1,815.38% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Tax Provisions (Quarterly) stood at $12,000 in 2021, then soared by 1,066.67% to $140,000 in 2022, then spiked by 60.71% to $225,000 in 2023, then plummeted by 356.00% to -$576,000 in 2024, then crashed by 175.50% to -$262,000 in 2025.
  • Its last three reported values are -$262,000 in Q3 2025, $402,000 for Q2 2025, and $1.0 million during Q1 2025.